The MHRA wants promising medical devices to reach NHS patients sooner, which is excellent news for innovation and devastating news for the nation’s forms, many of which have spent years training for a moment exactly like this.
In July, the regulator set out its intention to establish an Early Access service for innovative devices addressing unmet clinical needs. The proposed route could allow time limited, conditional access before full regulatory approval where there is clear clinical need and supporting evidence of benefit.
This is a sensible attempt to stop useful technology taking the scenic route through regulation. The service is initially intended to focus on innovative diagnostic devices supporting urgent NHS needs, while monitoring and safeguards remain in place. Nobody is suggesting that a machine should be admitted merely because it has an impressive casing and an instruction manual with excellent confidence.
What the proposal offers is a clearer path. What the existing system appears to offer is a series of doors marked nearly there, followed by a smaller door asking whether the first door has been properly documented.
Caradoc Pinch, Associate Director for Expedited Caution, is already preparing the new administrative vocabulary. Unnecessary delay will not be removed, he has apparently decided, but it may receive a more encouraging name and a coloured arrow.
That distinction matters. Medical devices need proper evidence, and patients need protection from products whose main innovation is persuading everyone that the missing evidence is somewhere else. The proposed service is meant to help promising tools move through assessment without turning the NHS into a showroom for anything that has survived a presentation.
The initiative also sits inside a wider programme of regulatory reform, with the MHRA referring to stronger post market surveillance and closer international collaboration. The device may be allowed through earlier, but somebody will still be watching it, recording what it does and asking it to explain itself in triplicate.
The larger breakthrough may therefore be administrative rather than technological. A regulator is trying to make access faster without pretending that safety is an optional loading screen. If successful, the new pathway could help useful devices reach patients before their inventors have forgotten why they built them.
At the closing meeting, the clipboard was granted conditional access to the next meeting, subject to evidence that it can remain flat under pressure. It has already appealed, citing years of relevant experience and an unblemished record of holding things together while everyone else loses the plot.
Source: Medicines and Healthcare products Regulatory Agency.
